Neurological biomarkers market projected to reach USD 26.6 billion by 2034 with 10.9% CAGR growth

From GlobeNewswire: 2025-01-23 05:30:00

The neurological biomarkers market was valued at USD 9.5 billion in 2024, with a projected 10.9% CAGR from 2025 to 2034. The increase in neurodegenerative disorders like Alzheimer’s and Parkinson’s is driving market growth, primarily due to an aging population. Personalized medicine and advanced technologies are enhancing early detection and treatment outcomes for patients.

Proteomic biomarkers led the market in 2024 at USD 3.1 billion, with advancements like LC-MS/MS improving test sensitivity. Alzheimer’s disease accounted for 45.5% of the market share, highlighting the need for early diagnostics. Blood-based biomarkers are becoming a more cost-effective alternative, driving market expansion.

Hospitals and clinics dominated the market in 2024 and are expected to reach USD 11 billion by 2034. Non-invasive biomarker diagnostics are improving patient outcomes through personalized care. Government support and research funding are accelerating the integration of biomarkers into routine clinical practice, benefiting both patients and healthcare providers.

The U.S. held a significant share of the market in 2024 at USD 3.7 billion, benefiting from technological advancements and a focus on precision medicine. The rise in demand for personalized therapies tailored to individual profiles is driving market growth. Major players in the market include Abbott Laboratories, Johnson & Johnson Services, and Thermo Fisher Scientific among others, driving further innovation and advancements in the field of neurological biomarkers.



Read more at GlobeNewswire: Neurological Biomarkers Market to hit USD 26.6 billion by